FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076923366> ?p ?o ?g. }

• W2076923366 endingPage "1128" @default.
• W2076923366 startingPage "1122" @default.
• W2076923366 abstract "β-elemene, a plant-derived drug extracted from Curcuma wenyujin, has demonstrated marked antiproliferative effects on glioblastoma, while toxicity remains low. However, the underlying molecular mechanisms of the antitumor activity of β-elemene remain to be elucidated. Previously, it was identified that the glia maturation factor β (GMFβ)/mitogen-activated protein kinase kinase (MAPK) 3/6/p38 pathway participates in the antiproliferative activity of β-elemene on glioblastoma. In the present study, in order to illustrate the association of GMFβ and the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway, U87 and U251 cells were treated with β-elemene at various doses and for different durations, and the expression of phosphorylated ERK1/2 (p-ERK1/2), ERK1/2, B-cell lymphoma 2 (Bcl-2), Bcl2-associated X and survivin was examined by western blot analysis. Following treatment with β-elemene and the ERK1/2 inhibitor PD98059, U87 cell viability was evaluated using a Cell Counting Kit-8 (CCK-8) assay, and the expression levels of Bcl-2 and survivin were examined by western blot analysis. GMFβ was then downregulated by RNA interference in β-elemene-treated U87 cells, and the effect of this on the expression of ERK1/2 and p-ERK1/2 was determined by western blot analysis. Finally, the chemosensitisation of U87 cells to temozolomide (TMZ) through β-elemene was examined using the CCK-8 assay. The results demonstrated that β-elemene inhibited the proliferation of U87 glioblastoma cells through the GMFβ‑dependent inactivation of the ERK1/2-Bcl-2/survivin pathway. Furthermore, inhibition of ERK1/2 by PD98059 enhanced the antitumor effect of β-elemene and impaired the expression levels of Bcl-2 and survivin. β-elemene also increased the sensitivity of U87 glioblastoma cells to the chemotherapeutic TMZ, which was synergistically enhanced by PD98059. In conclusion, these results suggested that GMFβ-dependent inactivation of the ERK1/2-Bcl-2/survivin pathway mediated the antiproliferative effect of β-elemene on glioblastoma. Therefore, β-elemene is a promising chemosensitizer or adjuvant therapeutic for TMZ against glioblastoma brain tumors." @default.
• W2076923366 created "2016-06-24" @default.
• W2076923366 creator A5000436738 @default.
• W2076923366 creator A5015733318 @default.
• W2076923366 creator A5039011448 @default.
• W2076923366 creator A5046659345 @default.
• W2076923366 creator A5063718730 @default.
• W2076923366 creator A5067028944 @default.
• W2076923366 creator A5084461414 @default.
• W2076923366 date "2014-05-27" @default.
• W2076923366 modified "2023-10-01" @default.
• W2076923366 title "β-Elemene inhibits proliferation through crosstalk between glia maturation factor β and extracellular signal-regulated kinase 1/2 and impairs drug resistance to temozolomide in glioblastoma cells" @default.
• W2076923366 cites W1535014461 @default.
• W2076923366 cites W1977133926 @default.
• W2076923366 cites W1997855401 @default.
• W2076923366 cites W1999057456 @default.
• W2076923366 cites W2005777593 @default.
• W2076923366 cites W2008329506 @default.
• W2076923366 cites W2016537150 @default.
• W2076923366 cites W2021272671 @default.
• W2076923366 cites W2023759379 @default.
• W2076923366 cites W2023808883 @default.
• W2076923366 cites W2027044194 @default.
• W2076923366 cites W2039840451 @default.
• W2076923366 cites W2046942093 @default.
• W2076923366 cites W2047100770 @default.
• W2076923366 cites W2049426430 @default.
• W2076923366 cites W2054828913 @default.
• W2076923366 cites W2058824071 @default.
• W2076923366 cites W2073924236 @default.
• W2076923366 cites W2090658654 @default.
• W2076923366 cites W2092008413 @default.
• W2076923366 cites W2120302274 @default.
• W2076923366 cites W2128246468 @default.
• W2076923366 cites W2130692001 @default.
• W2076923366 cites W2149831791 @default.
• W2076923366 cites W2150074953 @default.
• W2076923366 doi "https://doi.org/10.3892/mmr.2014.2273" @default.
• W2076923366 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24866280" @default.
• W2076923366 hasPublicationYear "2014" @default.
• W2076923366 type Work @default.
• W2076923366 sameAs 2076923366 @default.
• W2076923366 citedByCount "22" @default.
• W2076923366 countsByYear W20769233662014 @default.
• W2076923366 countsByYear W20769233662015 @default.
• W2076923366 countsByYear W20769233662016 @default.
• W2076923366 countsByYear W20769233662017 @default.
• W2076923366 countsByYear W20769233662018 @default.
• W2076923366 countsByYear W20769233662019 @default.
• W2076923366 countsByYear W20769233662020 @default.
• W2076923366 countsByYear W20769233662021 @default.
• W2076923366 countsByYear W20769233662022 @default.
• W2076923366 countsByYear W20769233662023 @default.
• W2076923366 crossrefType "journal-article" @default.
• W2076923366 hasAuthorship W2076923366A5000436738 @default.
• W2076923366 hasAuthorship W2076923366A5015733318 @default.
• W2076923366 hasAuthorship W2076923366A5039011448 @default.
• W2076923366 hasAuthorship W2076923366A5046659345 @default.
• W2076923366 hasAuthorship W2076923366A5063718730 @default.
• W2076923366 hasAuthorship W2076923366A5067028944 @default.
• W2076923366 hasAuthorship W2076923366A5084461414 @default.
• W2076923366 hasBestOaLocation W20769233661 @default.
• W2076923366 hasConcept C104317684 @default.
• W2076923366 hasConcept C1491633281 @default.
• W2076923366 hasConcept C153911025 @default.
• W2076923366 hasConcept C184235292 @default.
• W2076923366 hasConcept C185592680 @default.
• W2076923366 hasConcept C190283241 @default.
• W2076923366 hasConcept C2775975398 @default.
• W2076923366 hasConcept C2776415932 @default.
• W2076923366 hasConcept C2781340500 @default.
• W2076923366 hasConcept C29537977 @default.
• W2076923366 hasConcept C502942594 @default.
• W2076923366 hasConcept C53227056 @default.
• W2076923366 hasConcept C55493867 @default.
• W2076923366 hasConcept C57074206 @default.
• W2076923366 hasConcept C62478195 @default.
• W2076923366 hasConcept C86803240 @default.
• W2076923366 hasConcept C95444343 @default.
• W2076923366 hasConceptScore W2076923366C104317684 @default.
• W2076923366 hasConceptScore W2076923366C1491633281 @default.
• W2076923366 hasConceptScore W2076923366C153911025 @default.
• W2076923366 hasConceptScore W2076923366C184235292 @default.
• W2076923366 hasConceptScore W2076923366C185592680 @default.
• W2076923366 hasConceptScore W2076923366C190283241 @default.
• W2076923366 hasConceptScore W2076923366C2775975398 @default.
• W2076923366 hasConceptScore W2076923366C2776415932 @default.
• W2076923366 hasConceptScore W2076923366C2781340500 @default.
• W2076923366 hasConceptScore W2076923366C29537977 @default.
• W2076923366 hasConceptScore W2076923366C502942594 @default.
• W2076923366 hasConceptScore W2076923366C53227056 @default.
• W2076923366 hasConceptScore W2076923366C55493867 @default.
• W2076923366 hasConceptScore W2076923366C57074206 @default.
• W2076923366 hasConceptScore W2076923366C62478195 @default.
• W2076923366 hasConceptScore W2076923366C86803240 @default.
• W2076923366 hasConceptScore W2076923366C95444343 @default.
• W2076923366 hasIssue "2" @default.
• W2076923366 hasLocation W20769233661 @default.

• next